Cerebral glucose metabolism in dizygotic twin pairs discordant for Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 25, Issue 1, 2007, Pages 9-16

  Virta, Jyri J ^a   Karrasch, Mira ^c   Kaprio, Jaakko ^d,e   Koskenvuo, Markku ^a,d   Räihä, Ismo ^a,b   Viljanen, Tapio ^a   Rinne, Juha O ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU CITY HOSPITAL   (Finland)

^c ÅBO AKADEMI UNIVERSITY   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Alzheimer's disease; Cerebral glucose metabolism; Dizygotic twins

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DIZYGOTIC TWINS; ENVIRONMENTAL FACTOR; FEMALE; GENETIC ASSOCIATION; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; MALE; NEUROIMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; TEMPORAL CORTEX; TWIN DISCORDANCE;

AGED; ALZHEIMER DISEASE; BRAIN; COGNITION DISORDERS; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; QUESTIONNAIRES; REGISTRIES; TWINS, DIZYGOTIC;

EID: 37349027365     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111114     Document Type: Article

References (40)

1. Bergem AL, Engedal K, Kringlen E: The role of heredity in late-onset Alzheimer disease and vascular dementia: a twin study. Arch Gen Psychiatry 1997;54:264-270.
2. Breitner JC, Welsh KA, Gau BA, McDonald WM, Steffens DC, Saunders AM, Magruder KM, Helms MJ, Plassman BL, Folstein MF: Alzheimer's disease in the National Academy of Sciences-National Research Council Registry of Aging Twin Veterans. III. Detection of cases, longitudinal results, and observations on twin concordance. Arch Neurol 1995;52:763-771.
3. Raiha I, Kaprio J, Koskenvuo M, Rajala T, Sourander L: Alzheimer's disease in Finnish twins. Lancet 1996;347:573-578.
4. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL: Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006;63:168-174.
5. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, Heine-Suner D, Cigudosa JC, Urioste M, Benitez J, Boix-Chornet M, Sanchez-Aguilera A, Ling C, Carlsson E, Poulsen P, Vaag A, Stephan Z, Spector TD, Wu YZ, Plass C, Esteller M: Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005;102:10604-10609.
6. Petronis A: Epigenetics and twins: three variations on the theme. Trends Genet 2006;22:347-350.
7. Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, Casella V, Fowler J, Hoffman E, Alavi A, Som P, Sokoloff L: The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 1979;44:127-137.
8. Mosconi L: Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease: FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32:486-510.
9. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
10. De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Roche A, Tsui WH, Kandil E, Boppana M, Daisley K, Wang GJ, Schlyer D, Fowler J: Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529-539.
11. Chetelat G, Desgranges B, de lS, V, Viader F, Eustache F, Baron JC: Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003;60:1374-1377.
12. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi A: MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004;63:2332-2340.
13. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A: Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104-1113.
14. Kumar A, Schapiro MB, Grady CL, Matocha MF, Haxby JV, Moore AM, Luxenberg JS, George-Hyslop PH, Robinette CD, Ball MJ: Anatomic, metabolic, neuropsychological, and molecular genetic studies of three pairs of identical twins discordant for dementia of the Alzheimer's type. Arch Neurol 1991;48:160-168.
15. Luxenberg JS, May C, Haxby JV, Grady C, Moore A, Berg G, White BJ, Robinette D, Rapoport SI: Cerebral metabolism, anatomy, and cognition in monozygotic twins discordant for dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1987;50:333-340.
16. Small GW, Leuchter AF, Mandelkern MA, La Rue A, Okonek A, Lufkin RB, Jarvik LF, Matsuyama SS, Bondareff W: Clinical, neuroimaging, and environmental risk differences in monozygotic female twins appearing discordant for dementia of the Alzheimer type. Arch Neurol 1993;50:209-219.
17. Jarvenpaa T, Raiha I, Kaprio J, Koskenvuo M, Laine M, Kurki T, Vahlberg T, Viljanen T, Ahonen K, Rinne JO: Regional cerebral glucose metabolism in monozygotic twins discordant for Alzheimer's disease. Dement Geriatr Cogn Disord 2003;16:245-252.
18. Gatz M, Reynolds C, Nikolic J, Lowe B, Karel M, Pedersen N: An empirical test of telephone screening to identify potential dementia cases. Int Psychogeriatr 1995;7:429-438.
19. Jarvenpaa T, Rinne JO, Raiha I, Koskenvuo M, Lopponen M, Hinkka S, Kaprio J: Characteristics of two telephone screens for cognitive impairment. Dement Geriatr Cogn Disord 2002;13:149-155.
20. Sarna S, Kaprio J, Sistonen P, Koskenvuo M: Diagnosis of twin zygosity by mailed questionnaire. Hum Hered 1978;28:241-254.
21. Chandler MJ, Lacritz LH, Hynan LS, Barnard HD, Allen G, Deschner M, Weiner MF, Cullum CM: A total score for the CERAD neuropsychological battery. Neurology 2005;65:102-106.
22. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159-1165.
23. Brinkman SD, Largen JW Jr, Gerganoff S, Pomara N: Russell's revised Wechsler Memory Scale in the evaluation of dementia. J Clin Psychol 1983;39:989-993.
24. Wechsler D: Wechsler Adult Intelligence Scale - Revised. Cleveland, Psychological Corp, 1981.
25. Reitan RM: A Manual for the Administration and Scoring of the Trail Making Test. Bloomington, Indiana University Press, 1959.
26. Houx PJ, Jolles J, Vreeling FW: Stroop interference: aging effects assessed with the Stroop Color-Word Test. Exp Aging Res 1993;19:209-224.
27. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-238.
28. Cummings JL: Anatomic and behavioral aspects of frontal-subcortical circuits. Ann NY Acad Sci 1995;769:1-13.
29. Vataja R, Pohjasvaara T, Mantyla R, Ylikoski R, Leskela M, Kalska H, Hietanen M, Juhani AH, Salonen O, Kaste M, Leppavuori A, Erkinjuntti T: Depression-executive dysfunction syndrome in stroke patients. Am J Geriatr Psychiatry 2005;13:99-107.
30. Patlak CS, Blasberg RG: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab 1985;5:584-590.
31. Benson DF, Kuhl DE, Hawkins RA, Phelps ME, Cummings JL, Tsai SY: The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. Arch Neurol 1983;40:711-714.
32. Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, Ober BA, Huesman RH, Derenzo SE: Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr 1983;7:590-598.
33. McGeer PL, Kamo H, Harrop R, Li DK, Tuokko H, McGeer EG, Adam MJ, Ammann W, Beattie BL, Calne DB: Positron emission tomography in patients with clinically diagnosed Alzheimer's disease. CMAJ 1986;134:597-607.
34. Mosconi L, Tsui WH, Rusinek H, De Santi S, Li Y, Wang GJ, Pupi A, Fowler J, de Leon MJ: Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease. Eur J Nucl Med Mol Imaging 2007;34:1467-1479.
35. Stampfer MJ: Cardiovascular disease and Alzheimer's disease: common links. J Intern Med 2006;260:211-223.
36. Zlokovic BV: Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005;28:202-208.
37. Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, Liu D, Li F, Armstrong D, Gasiewicz T, Zidovetzki R, Song X, Hofman F, Zlokovic BV: Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med 2005;11:959-965.
38. Moscovitch M, Nadel L, Winocur G, Gilboa A, Rosenbaum RS: The cognitive neuroscience of remote episodic, semantic and spatial memory. Curr Opin Neurobiol 2006;16:179-190.
39. Clark CM, Klonoff H, Tyhurst JS, Ruth T, Adam M, Rogers J, Harrop R, Martin W, Pate B: Regional cerebral glucose metabolism in identical twins. Neuropsychologia 1988;26:615-621.
40. Thompson PM, Cannon TD, Narr KL, van Erp T, Poutanen VP, Huttunen M, Lonnqvist J, Standertskjold-Nordenstam CG, Kaprio J, Khaledy M, Dail R, Zoumalan CI, Toga AW: Genetic influences on brain structure. Nat Neurosci 2001;4:1253-1258.